Germany’s BPI CEO Visits Healthcare expo Taiwan, Opens Dialogue on Digital Health and Pharma Innovation

📣Unlock New BioTech Partnerships in Asia!
【2025 Registration Opens Now ▸ https://ibmi.pse.is/7mn2dd 】

In the face of worldwide healthcare challenges and emerging innovations, Dr. Kai Joachimsen, CEO of the German Pharmaceutical Industry Association (BPI), chose to visit the 2024 Healthcare+ Expo Taiwan. He not only participated in forums and exchanged insights but also explicitly affirmed Taiwan's strength in medical technology. He stated that his visit aimed to strengthen bilateral cooperation potential between Taiwan and Germany in pharmaceutical innovation, digital health (DiGA), and digital care (DiPA).

Dr. Kai Joachimsen, CEO of the German Pharmaceutical Industry Association (BPI), aimed to strengthen bilateral cooperation potential between Taiwan and Germany in pharmaceutical innovation, digital health (DiGA), and digital care (DiPA) during the 2024 Healthcare+ Expo Taiwan.

German Pharmaceutical Industry: Transformation Challenges on a Solid Foundation

As the world's fourth-largest pharmaceutical market, Germany's mature system and research capacity have always attracted global attention. Its healthcare system boasts a strong academic and research foundation, with overall and per capita healthcare spending among the highest in the world. However, under the pressure of an aging population, the German government is actively promoting digitalization and healthcare efficiency reforms. This transformation has also prompted German industry organizations, including BPI, to expand dialogues and collaborations with international partners.

Policy, Regulation, and Market-Oriented Cooperation: BPI Aims to Help Taiwanese Companies Enter Germany

At the B2B Meetup Forum held during the Expo, Dr. Joachimsen praised the Taiwanese government's commitment to supporting medical innovation. He noted that health is a global human pursuit, and stable policies and clear regulations are two pillars driving the health industry. Germany and Taiwan share many common foundations in this regard, which "lays a solid foundation for bilateral industrial dialogue." He believes Taiwan's pharmaceutical industry, especially its innovative research and promising companies, is showing vigorous vitality.

Meanwhile, he emphasized that BPI is not only a representative of the German domestic industry but also a bridge to help external partners enter the German market. He further explained Germany's market characteristics—most of the drugs that are being registered and approved can get a price reimbursement before pricing negotiations are completed and often serve as a price reference for other European countries. For Taiwanese companies, this is a gateway to the core European market.

Dr. Joachimsen learned about Taiwan’s latest medical technology advancements during a guided tour at the Expo.

Attractiveness of the German Pharmaceutical Market: Large Scale, High Stability, and Clear Innovation Orientation

For international partners seeking to expand into the European market, the German pharmaceutical market offers several attractive advantages. First, Germany is the world's fourth-largest pharmaceutical market after the U.S., China, and Japan, with 84 million residents, nearly all covered by health insurance, providing a large and accessible patient base for drugs and medical solutions. Second, Germany is regarded as the "touchstone" of the European market due to its professional market access system and high regulatory transparency. Entering the German market means having a ticket to the entire European market.

Moreover, Germany is actively investing in digital health applications, such as digital prescription drugs (DiGA) and digital care solutions (DiPA), integrating them into the healthcare insurance reimbursement system. This not only opens new markets but also opens doors to global companies with innovative software and hardware technologies.